Anaplastic Astrocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Anaplastic astrocytoma is a grade III tumor. It accounts for two percent of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. The Anaplastic Astrocytoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Anaplastic Astrocytoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.
Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Targets
The key targets of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf, Receptor Type Tyrosine Protein Kinase FLT3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Vimentin, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 4, and Cyclin Dependent Kinase 6.
Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Targets
For more target insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample
Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Mechanisms of Action
The key mechanisms of action of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cyclin Dependent Kinase 1 Inhibitor, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 4 Inhibitor, and Cyclin Dependent Kinase 6 Inhibitor.
Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Mechanisms of Action
For more mechanisms of action insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample
Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Anaplastic Astrocytoma pipeline drugs market are Oral, Intravenous, Intratumor, Intracerebral, Intradermal, Subcutaneous, Topical, and Ophthalmic.
Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample
Anaplastic Astrocytoma Pipeline Drugs Market Segmentation by Molecule Types
The key molecule types in the Anaplastic Astrocytoma pipeline drugs market are small molecule, oncolytic virus, monoclonal antibody, cell therapy, gene therapy, subunit vaccine, DNA vaccine, and gene-modified cell therapy.
Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Anaplastic Astrocytoma pipeline drugs market, download a free report sample
Anaplastic Astrocytoma Pipeline Drugs Market - Competitive Landscape
Some of the leading companies in the Anaplastic Astrocytoma pipeline drugs market are Bayer AG, Aettis Inc, Candel Therapeutics Inc, Cothera Bioscience Pty Ltd, Mustang Bio Inc, Nascent Biotech Inc, and Novartis AG.
Anaplastic Astrocytoma Pipeline Drugs Market Analysis, by Companies
To know more about the companies in the Anaplastic Astrocytoma pipeline drugs market, download a free report sample
Anaplastic Astrocytoma Pipeline Drugs Market Report Overview
Key Targets | Serine/Threonine Protein Kinase B Raf, Receptor Type Tyrosine Protein Kinase FLT3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Vimentin, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 4, and Cyclin Dependent Kinase 6 |
Key Mechanisms of Action | Serine/Threonine Protein Kinase B Raf Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cyclin Dependent Kinase 1 Inhibitor, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 4 Inhibitor, and Cyclin Dependent Kinase 6 Inhibitor |
Key Routes of Administration | Oral, Intravenous, Intratumor, Intracerebral, Intradermal, Subcutaneous, Topical, and Ophthalmic |
Key Molecule Types | Small Molecule, Oncolytic Virus, Monoclonal Antibody, Cell Therapy, Gene Therapy, Subunit Vaccine, DNA Vaccine, and Gene-Modified Cell Therapy |
Leading Companies | Bayer AG, Aettis Inc, Candel Therapeutics Inc, Cothera Bioscience Pty Ltd, Mustang Bio Inc, Nascent Biotech Inc, and Novartis AG |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Anaplastic Astrocytoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Anaplastic Astrocytoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Anaplastic Astrocytoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Anaplastic Astrocytoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Anaplastic Astrocytoma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Anaplastic Astrocytoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Anaplastic Astrocytoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
AbbVie Inc
Aettis Inc
AngioChem Inc
Apexigen Inc
Bayer AG
Berg LLC
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Candel Therapeutics Inc
CDG Therapeutics Inc
Cellix Bio Pvt Ltd
Chimerix Inc
Cothera Bioscience Pty Ltd
Curis Inc
Everfront Biotech Inc
Fore Biotherapeutics Inc
Geneos Therapeutics Inc
Ipsen SA
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Merck KGaA
MimiVax LLC
Mustang Bio Inc
Nascent Biotech Inc
Novartis AG
OncoSynergy Inc
Orbus Therapeutics Inc
Orphelia Pharma SAS
Otsuka Pharmaceutical Co Ltd
Pfizer Inc
PTC Therapeutics Inc
TheraBiologics Inc
Wayshine Biopharma Inc
Wuhan Binhui Biotechnology Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Anaplastic Astrocytoma pipeline drugs market?
The key targets of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf, Receptor Type Tyrosine Protein Kinase FLT3, Baculoviral IAP Repeat Containing Protein 5, Cells Expressing Vimentin, Cyclin Dependent Kinase 1, Cyclin Dependent Kinase 2, Cyclin Dependent Kinase 4, and Cyclin Dependent Kinase 6.
-
What are the key mechanisms of actions of the Anaplastic Astrocytoma pipeline drugs market?
The key mechanisms of action of the Anaplastic Astrocytoma pipeline drugs market are Serine/Threonine Protein Kinase B Raf Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, Cyclin Dependent Kinase 1 Inhibitor, Cyclin Dependent Kinase 2 Inhibitor, Cyclin Dependent Kinase 4 Inhibitor, and Cyclin Dependent Kinase 6 Inhibitor.
-
What are the key routes of administration in the Anaplastic Astrocytoma pipeline drugs market?
The key routes of administration in the Anaplastic Astrocytoma pipeline drugs market are Oral, Intravenous, Intratumor, Intracerebral, Intradermal, Subcutaneous, Topical, and Ophthalmic.
-
What are the key molecule types in the Anaplastic Astrocytoma pipeline drugs market?
The molecule types in the Anaplastic Astrocytoma pipeline drugs market are small molecule, oncolytic virus, monoclonal antibody, cell therapy, gene therapy, subunit vaccine, DNA vaccine, and gene-modified cell therapy.
-
Which are the leading companies in the Anaplastic Astrocytoma pipeline drugs market?
Some of the leading companies in the Anaplastic Astrocytoma pipeline drugs market are Bayer AG, Aettis Inc, Candel Therapeutics Inc, Cothera Bioscience Pty Ltd, Mustang Bio Inc, Nascent Biotech Inc, and Novartis AG.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.